Post by kc on Jul 31, 2014 16:49:49 GMT -5
blogs.wsj.com/pharmalot/2014/07/31/as-sanofi-pushes-to-grow-faster-a-key-u-s-exec-is-leaving/
Key SNY employee is leaving SNY?
Anne Whitaker, who joined Sanofi three years ago to run its North America pharmaceutical operations and help the drug maker push into lucrative markets such as diabetes, is leaving next month, according to an internal memo.
In a brief note to employees, Peter Guenter, an executive vice president for global commercial operations at Sanofi, wrote that Whitaker “played a central role in the transformation of our North American pharmaceutical business during a time of significant market evolution.”
He wrote that Whitaker is leaving for “another opportunity,” but further details on her next move were not available. A Sanofi spokeswoman sent us an e-mail that largely reiterated the contents of his memo. Whitaker could not be reached for comment.
ANOTHER OPPORTUNITY? Very interesting or perhaps nothing.
More to the article:
The days of making major profits on Lantus will go bye-bye. Their once aggressive broad strategy in diabetes has fallen apart,” says Kliff, who adds that other diabetes products are unlikely to win meaningful responses from payers or physicians. “The dominos are starting to fall. Either they make a major acquisition or they’re in serious danger of becoming irrelevant in diabetes.”
Viehbacher, meanwhile, is pressing ahead. Last month, Sanofi signed a deal with Medtronic, the big device maker, to develop combinations of drugs and devices to battle diabetes.
Key SNY employee is leaving SNY?
Anne Whitaker, who joined Sanofi three years ago to run its North America pharmaceutical operations and help the drug maker push into lucrative markets such as diabetes, is leaving next month, according to an internal memo.
In a brief note to employees, Peter Guenter, an executive vice president for global commercial operations at Sanofi, wrote that Whitaker “played a central role in the transformation of our North American pharmaceutical business during a time of significant market evolution.”
He wrote that Whitaker is leaving for “another opportunity,” but further details on her next move were not available. A Sanofi spokeswoman sent us an e-mail that largely reiterated the contents of his memo. Whitaker could not be reached for comment.
ANOTHER OPPORTUNITY? Very interesting or perhaps nothing.
More to the article:
The days of making major profits on Lantus will go bye-bye. Their once aggressive broad strategy in diabetes has fallen apart,” says Kliff, who adds that other diabetes products are unlikely to win meaningful responses from payers or physicians. “The dominos are starting to fall. Either they make a major acquisition or they’re in serious danger of becoming irrelevant in diabetes.”
Viehbacher, meanwhile, is pressing ahead. Last month, Sanofi signed a deal with Medtronic, the big device maker, to develop combinations of drugs and devices to battle diabetes.
